至 2010 年止中南美的心臟病治療市場趨勢

The Latin American Market Outlook to 2010 is a new management report which provides comprehensive coverage of the major cardiovascular markets in the Latin American region; this report provides detailed analysis of market trends, epidemiology, current leading brands of treatment, product sales forecast and future market leaders over the period 2005-2010 in ten markets: Brazil, Mexico, Argentina, Puerto Rico, Chile, Venezuela, Colombia, Ecuador, Peru, Uruguay. The Latin American cardiovascular market exhibits significant differences from both the global market and from other emerging cardiovascular markets. The high levels of public and private healthcare spending, means opportunities for price-competitive drugs, generics and modern branded drugs. Such opportunities differ vastly across this geographic region and indications, a reality that marketers must be aware of in order to achieve success.

This report will allow you to identify the right combination of products in your portfolio to achieve corporate success in a market that is significantly differentiated from all other regional cardiovascular markets .Reading this report will provide you with the tools to identify market trends in developed and emerging Latin American countries, assess the dominant forces driving market growth and develop potential growth and diversification opportunities in this region over the period 2005-2010.

Patient potential

Regional healthcare and licensing trends

Regional market analysis

Key players in the Latin American cardiovascular market

Chapter 1 Patient potential

Summary

Introduction

Disease description

Defining patient potential

Limitations of cardiovascular epidemiology data

Cardiovascular risk factors

Hypertension

Prevalence

Factors driving prevalence

Diagnosis, awareness and treatment of hypertension

Forecast prevalence of hypertension in Latin America

Dyslipidemia

Prevalence

Factors driving prevalence

Forecast prevalence of hypercholesterolemia in Latin America

Diabetes

Epidemiology of diabetes in Latin America

Prevalence

Forecast prevalence of diabetes

Cardiovascular disease

Prevalence

Acute thrombotic events

Acute coronary syndromes

Venous thromboembolism

Stroke

Chapter 2 Regional healthcare and licensing  trends

Summary

Introduction

Regional healthcare expenditure

Healthcare reforms

Healthcare financing

The external environment

Licensing analysis

Chapter 3 Regional market analysis

Summary

Introduction

Market breakdown by therapy area

Leading products

Market breakdown by country

Anti-hypertensives

Introduction

Analysis of the top 10 anti-hypertensives

Hypertension class sales by country, 2004

Market analysis by drug class

ACE inhibitors

Angiotensin receptor blockers

Beta blockers

Diuretics

Calcium channel blockers

Alpha-blocker/centrally acting hypertensives

Anti-hypertensives sales forecasts

Anti-dyslipidemics

Introduction

Analysis of the top 10 anti-dyslipidemics

Regional dynamics

Market analysis by drug class

Statins

Fibrates

Other anti-dyslipidemics

Anti-dyslipidemics sales forecasts

Anti-thrombotics

Introduction

Analysis of the top 10 anti-thrombotics

Regional dynamics

Market analysis by drug class

Anti-platelets

Heparins/low molecular weight heparins

Vitamin K antagonists

Fibrinolytics

Anti-thrombotics sales forecasts

Cardiac therapies

Introduction

Analysis of the top 10 cardiac therapies

Market analysis by drug class

Nitrites/nitrates

Anti-arrhythmics

Other cardiac therapy drugs

Cardiac therapies sales forecasts

Chapter 4 Key players in the Latin American cardiovascular market

Summary

Latin American market shares

Pfizer

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Sanofi-Aventis

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Merck & Co.

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Novartis

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

AstraZeneca

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Bristol-Myers Squibb

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Bayer

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Boehringer Ingelheim

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Chapter 5 Appendix 148

IMS sales data

Glossary

Index

�@

List of Figures

Figure 1.1: Relationship between cardiovascular disease and risk factors

Figure 1.2: Risk factors associated with hypertension

Figure 1.3: Estimated prevalence of obesity in twelve Eastern European market, 2005 and 2010

Figure 2.4: External analysis of the Eastern European region

Figure 3.5: Competitive dynamics in the Eastern European cardiovascular market, 2003.04

Figure 3.6: Competitive dynamics in the global anti-hypertensives market by drug class, 2003.

Figure 3.7: Competitive dynamics of leading Eastern European anti-hypertensives by leading brands, 2004

Figure 3.8: Competitive dynamics in the Eastern European anti-dyslipidemic market by drug 2003.04

Figure 3.9: Competitive dynamics of the top ten anti-dyslipidemic by drug class, 2004

Figure 3.10: Competitive dynamics in the Eastern European anti-thrombotic market by drug class, 2003.04

Figure 3.11: Competitive dynamics of the top ten anti-thrombotics in the Eastern European market by drug class, 2004

Figure 3.12: Competitive dynamics in the Eastern European cardiac therapy market by drug class, 2003.04

Figure 3.13: Competitive dynamics of the top ten cardiac therapy by drug class, 2004

Figure 4.14: Market share of key players in the Eastern European cardiovascular market, 2000 2004 List of

Tables

Table 1.1: Estimated prevalence of hypertension in twelve Eastern European markets, 2004

Table 1.2: Estimated prevalence of hypertension in twelve Eastern European markets, 2005.

Table 1.3: Estimated prevalence of dyslipidemia in twelve Eastern European markets, 2004

Table 1.4: Estimated prevalence of dyslipidemia in twelve Eastern European markets, 2005.

Table 1.5: Estimated prevalence of diabetes in twelve Eastern European markets, 2004

Table 1.6: Estimated prevalence of diabetes in twelve Eastern European markets, 2005.10

Table 1.7: Estimated prevalence of major cardiovascular diseases in the Eastern European market, 2004

Table 1.8: Estimated incidence of ACS in the Eastern European market, 2004

Table 1.9: Estimated incidence of VTE in the Eastern European market, 2004

Table 1.10: Prevalence of stroke in twelve Eastern European markets, 2004

Table 2.11: Recent statistics on healthcare sector in twelve Eastern European markets, 2002

Table 2.12: Public and private financing in twelve Eastern European markets, 2002

Table 2.13: Sales of types of cardiovascular brands in the Eastern European pharmaceutical market, 2000-04

Table 2.14: Sales of types of cardiovascular brands in twelve Eastern European markets, 2004

Table 3.15: Breakdown of Eastern European cardiovascular market by major therapeutic area, 2000.04

Table 3.16: Top 10 cardiovascular products in the Eastern European market, 2004

Table 3.17: Cardiovascular sales across twelve Eastern European markets, 2004

Table 3.18: Breakdown of Eastern European anti-hypertensives market by drug class, 2000.04

Table 3.19: Competitive dynamics of the Eastern European anti-hypertensives market by leading brands, 2004

Table 3.20: Market share of the leading classes of the anti-hypertensives in twelve Eastern European markets, 2004

Table 3.21: Breakdown of the ACE inhibitor market in the Eastern European market by leading brands, 2003.04

Table 3.22: Breakdown of the global CCB market by leading brands, 2003.04

Table 3.23: Breakdown of the Eastern European beta-blocker market by leading brands, 2003.

Table 3.24: Breakdown of the performance of drugs outside the major classes in the Eastern European market by leading brands, 2003.04

Table 3.25: Sales forecasts for drug classes within the Eastern European anti-hypertensives market, 2004.10

Table 3.26: Breakdown of the Eastern European anti-dyslipidemics market by drug class, 2000.

Table 3.27: Breakdown of Eastern European anti-dyslipidemic market by leading brands, 2004

Table 3.28: Anti-dyslipidemics market share in twelve Eastern European markets, 2004

Table 3.29: Sales forecasts for drug classes within the Eastern European anti-dyslipidemics market, 2004.10

Table 3.30: Breakdown of Eastern European anti-thrombotic market by drug class, 2000.04

Table 3.31: Breakdown of Eastern European anti-thrombotic market by leading brands, 2004

Table 3.32: Sales forecasts for drug classes within the Eastern European anti-thrombotics market, 2004.10

Table 3.33: Breakdown of Eastern European cardiac therapy market by drug class, 2000.04

Table 3.34: Breakdown of the Eastern European cardiac therapy market by leading brands, 2004

Table 4.35: Key players in the Eastern European cardiovascular market, 2000.2004

Table 4.36: Servier s marketed cardiovascular portfolio, 2003-04

Table 4.37: Servier s cardiovascular R&D pipeline, 2005

Table 4.38: Forecast sales for Servier s cardiovascular portfolio, 2004.10

Table 4.39: Sanofi-Aventis  marketed cardiovascular portfolio, 2003-04

Table 4.40: Sanofi-Aventis  cardiovascular R&D pipeline, 2005

Table 4.41: Forecast sales for Sanofi-Aventis  cardiovascular portfolio, 2004-10

Table 4.42: Pfizer s marketed cardiovascular portfolio in Eastern European market, 2003-04

Table 4.43: Pfizer s cardiovascular R&D pipeline, 2005

Table 4.44: Forecast sales for Pfizer s Eastern European cardiovascular portfolio, 2004.10

Table 4.45: Novartis  marketed cardiovascular portfolio, 2003-04

Table 4.46: Novartis  cardiovascular R&D pipeline, 2005

Table 4.47: Forecast sales for Novartis s cardiovascular portfolio, 2004.10

Table 4.48: Krka s marketed cardiovascular portfolio, 2003-04

Table 4.49: Forecast sales for Krka s cardiovascular portfolio, 2004.10

Table 4.50: Zentiva s marketed cardiovascular portfolio, 2003-04

Table 4.51: Forecast sales for Zentiva s cardiovascular portfolio, 2004.10

Table 4.52: Gedeon Richter s marketed cardiovascular portfolio, 2003-04

Table 4.53: Forecast sales for Gedeon Richter s cardiovascular portfolio, 2004.10

Table 4.54: Merck & Co s marketed cardiovascular portfolio, 2003-04

Table 4.55: Merck & Co s cardiovascular R&D pipeline, 2005

Table 4.56: Forecast sales for Merck & Co s cardiovascular portfolio, 2004.10